HOME >> BIOLOGY >> NEWS
Researchers test new therapy for advanced melanoma

Tampa, FL (March, 25, 2005) --Melanoma is a particularly deadly form of skin cancer very resistant to treatment. Researchers at H. Lee Moffitt Cancer Center & Research Institute and the University of South Florida are testing a promising new therapy that prompts the immune system to aid in the fight against melanoma tumors.

"This is a milestone clinical trial because it is the first time that electroporation is being used to deliver plasmid DNA in a gene therapy study in humans," said Richard Heller, PhD, USF professor of medical microbiology and immunology who helped develop the technology used in the study.

Electroporation is a technique in which a hand-held device applied to the skin delivers pulses of electricity to open up pores in the tumor cell membrane. This opening allows a small therapeutic molecule -- in this case a molecule known as a DNA plasmid that contains the gene for Interleukin-12 -- to slip inside the melanoma tumor before the membrane reseals.

"Melanoma does not respond well to standard chemotherapy," said Adil Daud, MD, assistant professor of oncology in the Cutaneous Oncology Program at Moffitt. "Gene therapy gives us the flexibility to introduce a huge variety of potential targets for treatment, but its major limitation has been getting the gene into the cancer. If electroporation can deliver the gene to these tumors reliably and without serious side effects, melanoma and other cancers would be open to many new treatment possibilities."

Six years of laboratory studies by Dr. Heller and his colleagues preceded the initial human trial begun earlier this year at Moffitt. The collaboration of USF and Moffitt in this trial is a good example of translational research -- moving the new application of a gene transfer technology from an animal model to the patient. Dr. Heller's team worked extensively with Dr. Daud to adapt the electroporation technique used on mice to humans.

The researchers injected the
'"/>

Contact: Anne DeLotto Baier
abaier@hsc.usf.edu
813-974-3300
University of South Florida Health
5-Apr-2005


Page: 1 2

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: